Immune Effects of Escalating Doses of Granulocyte-Macrophage Colony-Stimulating Factor Added to a Fixed, Low-Dose, Inpatient Interleukin-2 Regimen: A Randomized Phase I Trial in Patients With Metastatic Melanoma and Renal Cell Carcinoma